According to the recent research report titled ‘GLOBAL DNA VACCINES MARKET 2019-2027’, available with Market Study Report, global DNA vaccines market is projected to witness a robust y-o-y growth rate of 42.03% during 2019-2027.
 

Increasing instances of infectious and chronic diseases, growing use of DNA vaccines for animal healthcare applications, and surging development of new vaccines are the key factors driving the growth of global DNA vaccines market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2487414/
 

For those uninitiated, DNA vaccines are third-generation vaccines that comprises of a DNA which is accountable for coding of certain proteins (antigens) from pathogens. The human or animal cells are injected with genetically engineered DNA in order to produce antigens through a defensive immunological response.
 

Moreover, DNA vaccines, unlike traditional vaccines, use DNAs only from infectious species. Such DNAs have no possible risk of infection and possess both cell-mediated and humoral immunity, thereby stimulating the industry outlook.
 

DNA vaccines can trigger a wide variety of immune responses and are thus thoroughly studied for the possible benefits of curing diseases such as cancer, HIV/AIDS, and others, which in turn is augmenting global DNA vaccines market share.
 

In addition, growing inclination towards steady vaccines since they are easy to store and transport, increasing number of clinical trails on human as well as escalating demand for gene therapy are also contributing to the overall market growth.
 

However, stringent rules by the government and dearth of legal & ethical framework may hamper the industry expansion over the analysis period.
 

Based on type, global DNA vaccines market is divided into human and animal DNA vaccine. Speaking of application spectrum, the industry is bifurcated into veterinary and human diseases. Moving on to technology type, the market is split into plasmid DNA delivery and plasmid DNA vaccines.
 

Citing the regional landscape, worldwide DNA vaccines market is segmented into Middle East & Africa (MEA), Asia Pacific, North America, Europe, and Latin America. The report states that North America currently holds considerable share in global DNA vaccines market, primarily due to high investments to encourage development of human DNA vaccines in Canada and the U.S.
 

Major contenders in global DNA vaccines market are Eurogentec S.A., Xenetic Biosciences Inc., Inovio Pharmaceuticals Inc., Dendreon Corporation (Sanpower Group), Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, Madison Vaccines Incorporated (MVI), Merial Limited (Boehringer Ingelheim), Sanofi S.A., Vical, Incorporated, Merck & Co., VGXI, Zoetis Inc,, and Novartis AG.